<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297216</url>
  </required_header>
  <id_info>
    <org_study_id>17-1173</org_study_id>
    <secondary_id>1R01HD087119</secondary_id>
    <nct_id>NCT03297216</nct_id>
  </id_info>
  <brief_title>Improving Pregnancy Outcomes With Progesterone</brief_title>
  <acronym>IPOP</acronym>
  <official_title>Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, double-masked, placebo-controlled, randomized controlled trial taking
      place in Zambia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Weekly intramuscular injections of 250mg 17-alpha hydroxyprogesterone caproate (17P) or
      indistinguishable placebo will be randomly allocated in a 1:1 ratio started between 16-24
      weeks gestation and administered weekly thereafter until 36 6/7 gestational weeks,
      stillbirth, or delivery, whichever is sooner.

      Individual participants will be followed from enrollment (prior to 24 weeks gestation)
      through 42 days postpartum.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, double-masked, placebo-controlled, randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Number of Preterm Births or Stillbirths</measure>
    <time_frame>From date of randomization (between 16 and 24 weeks gestation) until the date of delivery or stillbirth, up to a total of approximately 28 weeks</time_frame>
    <description>A composite of live births prior to 37 weeks of gestation or stillbirth occurring at any gestational age</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pre-term Birth</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>250 mg 17P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly intramuscular injection of 250mg 17P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>weekly intramuscular injection of indistinguishable placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17P</intervention_name>
    <description>Synthetic progestin</description>
    <arm_group_label>250 mg 17P</arm_group_label>
    <other_name>17-alpha hydroxyprogesterone caproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-active placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  less than 24 0/7 weeks of gestation

          -  viable intrauterine singleton pregnancy confirmed by ultrasound

          -  antibody-confirmed HIV-1 infection

          -  currently receiving ART or intending to commence ART in pregnancy

          -  ability and willingness to provide written informed consent

          -  intent to remain in current geographical area of residence for the duration of study

          -  willing to adhere to weekly study visit schedule

        Exclusion Criteria:

          -  confirmed prior spontaneous preterm birth

          -  multiple gestation

          -  known uterine anomaly

          -  planned or in situ cervical cerclage

          -  major fetal anomaly detected on screening ultrasound

          -  indication for planned delivery prior to 37 weeks (e.g. prior classical cesarean)

          -  threatened abortion, preterm labor, or ruptured membranes at time of enrollment

          -  known allergy or medical comorbidity listed as a contraindication to 17P in the
             prescribing information

          -  prior participation in the trial

          -  any other condition (social or medical) which, in the opinion of the study staff,
             would make trial participation unsafe or complicate data interpretation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Stringer, MD, FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kamwala District Clinic</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PreTerm Birth</keyword>
  <keyword>HIV-1-infection</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

